Biogen Gets First US Tocilizumab Biosimilar

FDA Approves Bio-Thera-Partnered Tofidence; Biogen Is ‘Evaluating Launch Timeline’

Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said it was “currently evaluating the potential launch timeline.”

Tocilizumab vial in foreground
Biogen and Bio-Thera’s tocilizumab biosimilar has received FDA approval • Source: Shutterstock

Biogen has obtained the first US Food and Drug Administration approval for a biosimilar rival to Actemra (tocilizumab), in the form of its Tofidence (tocilizumab-bavi) intravenous version.

Key Takeaways:

  • Tofidence is the first tocilizumab biosimilar approved by the FDA

Developed by partner Bio-Thera Solutions under the codename BAT1806/BIIB800, Tofidence has become “the first tocilizumab biosimilar to gain FDA...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.